12 September 2023>: Original Paper
Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study
Kohei Ogawa ABCDEF* , Kei Tamura AB , Katsunori Sakamoto C , Naotake Funamizu B , Masahiko Honjo B , Mikiya Shine B , Yusuke Nishi B , Tomoyuki Nagaoka B , Chihiro Ito B , Miku Iwata B , Mio Uraoka B , Yasutsugu Takada ADDOI: 10.12659/AOT.941346
Ann Transplant 2023; 28:e941346
Table 4 Comparisons of clinical factors and outcomes among donor-specific anti-human leukocyte antigen antibody (DSA)-positive, cross-reactive epitope group antibody (CREG)-alone-positive, and double-negative liver transplant recipients.
Characteristic | DSA-positiven=9 | CREG-alone-positiven=7 | Double-negativen=21 | p-value |
---|---|---|---|---|
Age, median (range), y | 59 (37–67) | 50 (24–70) | 53 (24–69) | 0.47 |
Sex, n, male/female | 2/7 | 3/4 | 12/9 | 0.21 |
MELD score, median (range) | 15 (9–28) | 15 (6–21) | 13 (6–40) | 0.49 |
Primary disease, n | PBC: 1 | PBC: 1 | ALF: 3 | 0.47 |
LC (HCV): 2 | BA: 1 | LC (HCV): 4 | ||
LC (alcohol): 2 | LC (HCV): 1 | LC (HBV): 4 | ||
LC (NASH): 2 | LC (HBV): 1 | LC (alcohol): 4 | ||
Other: 1 | LC (NASH): 1 | LC (NASH): 2 | ||
Graft failure: 1 | BA: 2 | |||
Other: 1 | Graft failure: 1 | |||
Other: 1 | ||||
ABO-incompatible, n (%) | 2 (22) | 0 | 6 (29) | 0.28 |
Preoperative desensitization therapy, n (%) | 7 (78) | 2 (29) | 6 (29) | |
Donor age, median (range), y | 33 (24–64) | 46 (21–59) | 44 (21–64) | 0.33 |
Graft type, n, right/left/posterior | 7/2/0 | 5/2/0 | 16/3/2 | 0.70 |
GRWR, median (range),% | 0.99 (0.79–1.32) | 0.82 (0.67–1.17) | 0.94 (0.63–1.34) | 0.22 |
Operative time, median (range), min | 647 (551–909) | 867 (610–1021) | 788 (578–1002) | 0.11 |
CIT, median (range), min | 57 (30–110) | 91 (37–233) | 70 (27–298) | 0.28 |
WIT, median (range), min | 53 (32–63) | 49 (39–82) | 47 (32–95) | 0.66 |
Blood loss, median (range), g | 3400 (850–21,064) | 5900 (760–17,910) | 4560 (670–34,960) | 0.59 |
TCMR, n (%) | 2 (22%) | 3 (43%) | 6 (29%) | 0.66 |
AMR, n (%) | 1 (11%) | 0 | 2 (10%) | 0.68 |
CMV infection, n (%) | 2 (22%) | 4 (57%) | 12 (57%) | 0.19 |
Bacteremia, n (%) | 0 | 1 (14%) | 1 (5%) | 0.45 |
Biliary complications | 1 (11%) | 2 (29%) | 4 (19%) | 0.68 |
90-day mortality, n (%) | 0 | 0 | 1 (5%) | 0.68 |
Follow-up, median (range), days | 987 (518–2415) | 1148 (952–2247) | 1436 (66–2520) | 0.48 |